• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

MedAlliance picks up FDA IDE nod for drug-eluting balloon

January 10, 2023 By Sean Whooley

MedAlliance SELUTION SLRMedAlliance announced today that its novel sirolimus-eluting balloon received conditional FDA investigational device exemption (IDE).

Geneva, Switzerland-based MedAlliance can now initiate its pivotal clinical trial for the treatment of coronary de novo lesions.

MedAlliance received its first IDE for Selution SLR in below-the-knee indications in May 2022. It picked up a second IDE in August. Those regulatory nods cover occlusive disease of the superficial femoral artery (SFA) and coronary in-stent restenosis (ISR).

The company expects to enroll in its Selution SLR coronary de novo study in the U.S. within the next few months. That trial will complement its European de novo study of more than 800 patients (3,326 planned). The trial evaluates Selution SLR against any sirolimus drug-eluting stent (DES), attempting to demonstrate the superiority of the balloon over the stent in treating coronary de novo artery disease.

“Coronary de novo lesions are the largest potential opportunity for use of [drug-eluting balloons]: the data has shown clearly that DES don’t work well in small vessels, long, or bifurcated lesions or in patients with diabetes or risk of high bleeding complications,” said MedAlliance Chair and CEO Jeffrey Jump. “These patients represent 60% of all patients currently treated with DES, who may now benefit from this exciting new DEB technology.”

About the MedAlliance Selution SLR drug-eluting balloon

Selution SLR provides a controlled sustained drug release, similar to a drug-eluting stent. It features unique micro-reservoirs made of biodegradable polymer intermixed with sirolimus. The micro-reservoirs provide a controlled and permanent release of the drug for up to 90 days. MedAlliance’s CAT (cell-adherent technology) allows microdeposits to coat the balloons and adhere to the vessel lumen when delivered through an angioplasty balloon.

The system received CE mark approval for treating peripheral artery disease (PAD) in 2020. CE mark for treating coronary artery disease followed in May 2020.

MedAlliance says Selution SLR was the first drug-eluting balloon (DEB) to garner FDA breakthrough device designation. The first came in March 2019, followed by September 2019, for below-the-knee indications in PAD.

It holds four total FDA breakthrough device designations. They cover the treatment of atherosclerotic lesions in innate coronary arteries, coronary in-stent restenosis, peripheral diseases below the knee and indications for arteriovenous fistula.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Vascular Tagged With: FDA, MedAlliance

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS